ly3437943 retatrutide triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Triple GLP-1 / GIP /
Description
What the clinical research actually says about GLP-1 receptor agonists and alcohol cravings
Fertility Considerations After Stopping GLP-1 Medications Some women report changes in menstrual cycles and ovulation after stopping semaglutide or tirzepatide
Semaglutide and tirzepatide both offer effective weight loss with potentially different side effect profiles for your body
Several studies point to a protective role of GLP-1RAs on retinal pigment epithelium (RPE) cells, which form the blood-retinal barrier and are vulnerable to inflammation [83, 84]
The latest published evidence will be reviewed with an emphasis on its limitations and clinical implications. Beyond these serious adverse events, GLP-1 receptor agonists come with a black box warning about the risk for medullary thyroid cancer based on rodent models
GPR142 prompts glucagon-like Peptide-1 release from islets to improve beta cell function
